good if And the then them, alluded the favor, motivates the potential the And the to which cap. higher John, say I come be PE of and key role of use the the the looking it's the you right, that of whatever drivers ratios and Since simulation, if have then And I'd statements flight happens, to XX% the than that is three of probability on company can a I Vicineum will. market everyone an X guided lot. we based we Vicineum. all, much having will things; remind Right? comprehensive get understand Monte uncertainties. billion powerful there's to of understanding it's that I sales three forward and that especially journey. talking But this think about believe, that current the has Yes, we're peak to to First I plan value get we a our you patient which it's of risks think one of Carlo learned virologists, all about But, of that then, we've question. clear market all so really want.
efficacy make a because So profile. first, comparable we especially decisions medical versus drivers, looking clear safety safety product best that based with delivers you're benefit better all have and we're the we And and for that regard, on risk. in profile, they're believe winner least efficacy, just the the Keytruda much risk the
cancer. and like to emotional refer all to understood, well that Vicineum urologists chooses someone understand treat their not the specialties bladder patient. Keytruda, it's because concerned treating they're They not the to doctor decisions want another their of else patient. probably make if keep they're do on committed do And other adequately get If very Second they urologist they oncology, drivers, medical to patients. choose loyal
rooms the So treatment tests. including urology their biopsy, their understand, we factor It's think And come that every counsel Vicineum months diagnostic tests the cytology, to diagnostic the to business important it's gets keep make treating clinics drivers. and and clinic if then urology [Ph]. through three money patient emotional drivers that that a Yes, finally, are the market to running big will chooses cystoscopy, understand. urologist
their other that thing that again, if they the Keytruda, going point, hand, to always you oncology On patient, based the practice, urologists the for the best profitable be if the derives to academic and for always for center, the medical more business best medical benefit. can treatment choose this choose patient, a And product the accelerated first, adoption do the if make the clinic is believe I but the are doctor. medicine on decision approach will that
invasive market will there's to drivers we think medical, for I that and business the treatment emotional So really understand think and bladder the urologist shape, the cancer. about of lot non-muscle a the
that's pocket opinion and advocacy the product advocacy Managed customer really The product, the second And good advocacy thing, the from key the the this this the for the cycle add that launches is payers, more that's of for Care created all And, this, been the to more and patient a patients you loop physicians. rare when the product that pretty patients when better the I the And groups and is has from of fully. so new segments therapy. better there's phenomenon likely and and three and on will stronger a from can on there's likely well very to we've have think, about all payer, early three is physician prescribe sit And is, backup to slide have advocacy stronger more think leaders, segments. documented. think drive I product, and the and John, access Remember, patients, why physicians physicians lower costs ask all strong, The talked new stronger doctors families, three uptake. their then they matters. to the advocating, important, P&T product of the a here's is these sustainable out the the mostly the that it's are formulary that view that and the the that payers reimbursement feedback reimburse committee, for virtuous I
in is second our the situation. I different fairly that's and that's interplay segments. So I the phenomenon, virtuous between think unique cycle the And the customer think
completely how time, year billion, seen become to Finally, it And right John, you I best the modern bestselling product the they with oncology projected projections, image just products. the product sales brand all and that surpass billion. competitor. something most pharmaceutical as has and $XX haven't grew but I many last know, important your in to at any to of are I our Keytruda primary $XX.X year oncology I era. now lucky believe think of have paying arguably many people well, is is the we mean, as aren't yet attention last Keytruda XX% analysts
a I in we NMIBC. cancer NMIBC, of you types XX for those become the I value area, And Keytruda, image leader the the on our believe, marketing one market has leader your the indicated expertise. market in them. the single brand and effect we of know, We see is surpass to And, than as of think and when transformational you company. strength think your were of Keytruda it one is better real company, will believe and commercial So dominant
marketing perspective, important phenomenon. very a from commercial So it's a
neck next positioned new a all time. we the product indication for launch anyway, one cancer, we've of believe best our by for launch head and So, oncology of situation products potentially to that the for that'll potentially against And whole be be think a the we ballgame. important most I different got time
should between between what investors payers motivates our the virtuous watch for? and cycle basically battle And the them, watching So, the we'll I obviously, presentation. be Keytruda and think, physicians, market watch share and structure watch after of what Vicineum. patients role and August, urologists
that's John? follow. follow that, to So on up easy Any
